Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
18 results
  • Pancreatic Cancer, Melanoma, Lung Cancer, Colorectal Cancer

21-184          Phase I

A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations (View details on

  • Pancreatic Cancer, Sarcoma, Liver Cancer, Endometrial Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Bladder Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on

  • Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Melanoma

22-595          Phase II

A Phase 1/2A Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination with BGB-3245 in Patients with Advanced Solid Tumors (View details on

  • Cervical Cancer, Gastric (Stomach) Cancer, Lung Cancer, Endometrial Cancer, Ovarian Cancer, Esophageal Cancer, Pancreatic Cancer, Head and Neck Cancer, Breast Cancer

22-015          Phase I

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a SA and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (View details on

  • Colorectal Cancer, Gastric (Stomach) Cancer, Pancreatic Cancer

22-129          Phase II

A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3) (View details on

  • Pancreatic Cancer, Colorectal Cancer, Lung Cancer

20-671          Phase II

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation (View details on

  • Pancreatic Cancer

20-607          Phase II

A phase II, open label, randomized, parallel arm study of NIS793 (with or without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) (View details on

  • Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma

21-471          Phase I

An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (View details on

  • Gallbladder and Bile Duct Cancers, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer

21-121          Phase II

First in Human Phase 1/2 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors (View details on

Showing 1 - 10 of 18 results